Latest News for: UCB
Edit
Acquisition of own shares (UCB SA)
Public Technologies 20 Mar 2026
In accordance with article 8.4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, UCB SA/NV ("UCB" or the "Company") (Euronext Brussels.
Edit
Wale Announces “Live in the District” Juneteenth Weekend Concert Series in D.C.
The Source 20 Mar 2026
Wale is bringing a major hometown moment to Washington, D.C ... .
Edit
Epilepsy Market: Expanding Revenue Landscape to 2034 – DelveInsight | ES Therapeutics, PhytoTech Therapeutics, UCB ...
GetNews 16 Mar 2026
Get a Free sample for the Epilepsy Market Report. Some of the key facts of the Epilepsy Market Report. ... In March 2026, Xenon Pharmaceuticals announced plans to seek U.S ... Following the announcement, the company’s shares rose by about 48% on Monday.
Edit
Share Repurchase Program 2026 to cover UCB's Long Term Incentive Plans for employees (UCB SA)
Public Technologies 13 Mar 2026
In application of article 7.215 of the Belgian Code of Companies and Associations, UCB SA/NV ("UCB" or the "Company") (Euronext Brussels ... UCB, Brussels, Belgium (www.ucb.com) is a ...
Edit
Driving change for epilepsy care in Rwanda (UCB SA)
Public Technologies 12 Mar 2026
We recently travelled to Rwanda with a film crew as they filmed a new mini-documentary, produced for UCB by BBC StoryWorks, about epilepsy care in the country ... This video was produced for UCB by BBC StoryWorks Commercial Productions.
Edit
BIMZELX[®]▼(bimekizumab) superior to SKYRIZI[®] (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50 (UCB SA)
Public Technologies 11 Mar 2026
Email [email protected] / [email protected] ... UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and ...
Edit
Bimzelx (UCB) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, 2020-2025, 2025-2030F, 2035F
Nasdaq Globe Newswire 10 Mar 2026
Edit
International Women’s Day 2026: When we give women of childbearing age the data they deserve, we all gain (UCB SA)
Public Technologies 06 Mar 2026
Edit
Lincoln Times-News
04 Mar 2026
Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for ...
Lincoln Times-News
04 Mar 2026
Edit
UCB and Antengene enter global license agreement for ATG-201, a B cell-depleting bispecific antibody
Pharmiweb 04 Mar 2026
Edit
UCB and Antengene enter global license agreement for ATG-201, a B cell-depleting bispecific antibody (UCB SA)
Public Technologies 03 Mar 2026
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with ...
Edit
Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases
PR Newswire 03 Mar 2026
Edit
Strong execution in service of patients and sustainable value (UCB SA)
Public Technologies 26 Feb 2026
) ... I would like to thank all UCB colleagues for their dedication this year ... Attachments Original document Permalink. Disclaimer. UCB SA published this content on February 26, 2026, and is solely responsible for the information contained herein ... (noodl.
Edit
Strong Execution Fueling Sustained Company Growth (UCB SA)
Public Technologies 26 Feb 2026
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with ...
Edit
Rare Disease Day: More than you can imagine (UCB SA)
Public Technologies 24 Feb 2026
). Rare Disease Day highlights resilience and the need for action ... Rare Disease Day is more than a date on the calendar ... Beyond Medicine ... UCB SA published this content on February 24, 2026, and is solely responsible for the information contained herein.
- 1
- 2
- Next page »